Fluciclovine PET scan to check for leftover tumor after brain metastasis surgery
Tests 18F-Fluciclovine PET imaging in people after surgery for brain metastases.
Key facts
- Who runs it
- Baptist Health South Florida
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 10 Jan 2023
- Expected to end
- Jan 2030
- Type of study
- Interventional
- Treatments tested
- 18F-Fluciclovine
- Record updated
- 1 December 2025
Who can take part
The trial is looking for adults with cancer that has spread to the brain (brain metastasis). They must be planned for surgery and then focused radiation (SRS) after surgery.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Brain metastasis seen on scans. Surgery is planned for at least 1 metastasis, then SRS after surgery. Daily activity level ECOG 0-3.
- Earlier treatment
- People who have had whole-brain radiation therapy before cannot join.
- Main reasons for not taking part
- Severe allergic reaction (anaphylaxis) to 18F-Fluciclovine in the past
- Signs of cancer in the lining of the brain and spinal cord (leptomeningeal disease)
- Cannot have an MRI, for example because of a pacemaker
- Pregnant at the time of the 18F-fluciclovine scan
- Breastfeeding and not willing to stop for 24 hours after the scan
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Age ≥ 18 years
- Performance status, Eastern Cooperative Oncology Group (ECOG) 0-3
- Radiographic diagnosis of brain metastasis
- Patient planned for surgical intervention for at least 1 metastasis
- Patient planned for postoperative SRS; Male or female patients of reproductive potential need to employ two highly effective and acceptable forms of contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 1 week after post-treatment 18F-Fluciclovine PET/CT. Highly effective and acceptable forms of contraception are:
- Male condom plus spermicide
- Cap plus spermicide
- Diaphragm plus spermicide
- Copper T
- Progesterone T
- Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
- Implants
- Hormone shot or injection
- Combined pill
- Mini-pill
- Patch; Postmenopausal people on the study (that will not need contraception) is defined as at least one of the following:
- Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
- Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50
- Radiation-induced oophorectomy with last menses > 1 year ago
- Chemotherapy-induced menopause with >1 year interval since last menses
- Surgical sterilization (bilateral oophorectomy or hysterectomy)
Who cannot take part
- Prior anaphylactic reaction to 18F-Fluciclovine
- Prior whole-brain radiation therapy
- Evidence of leptomeningeal disease
- Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)
- Pregnant at the expected time of 18F-fluciclovine administration
- Expecting to be breastfeeding at the time of 18F-Fluciclovine and unwilling to stop breast-feeding for 24 hours. Temporary cessation of breastfeeding 24 hours after the time of imaging is allowed
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Brain metastases or brain cancer
This trial is currently available in United States.
- Miami Cancer Institute at Baptist Health South FloridaMiami, United StatesContact: Rupesh Kotecha, MDTaking people
About the trial
What the trial wants to find out
This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.
The group in the trial
- PET/CT, MRITreatment being tested
All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.
Treatment: 18F-Fluciclovine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
- Plain-language title
- Fluciclovine PET scan to check for leftover tumor after brain metastasis surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT05554302, who can take part
- Record updated
- 1 December 2025